Consensus Alvotech Nyse

Equities

ALVO

LU2458332611

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.15 ^USD	+3.66%		+7.03%	+50.85%

Apr. 25	Cigna to offer Humira rivals with $0 copay at specialty pharmacy	RE
Apr. 24	Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	MT

Evolution of the average Target Price on Alvotech

Price target over the last 5 years

History of analyst recommendation changes

83197e9ff1c6ded913be.U-bpIrmvyTK5fWbh-JdEQLe7L68z38VcFbesHL_ycrk.IZDQcN33okjsRCPWu_EzLNzwaPdxlI8Vff-BVO23H94Vv6tF85-Bf4gHVg~cd9db50d9aff1ec01e6c9411f5f1b20d

Analyst Recommendations on Alvotech

Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	Mar. 22	MT
Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	Jan. 29	MT
Citigroup Upgrades Alvotech to Neutral From Sell, Adjusts Price Target to $10 From $5	23-10-20	MT
Barclays Initiates Alvotech With Equalweight Rating, Price Target is $10	23-09-21	MT
Deutsche Bank Adjusts Alvotech Price Target to $8 From $12, Maintains Hold Rating	23-06-30	MT
Deutsche Bank Adjusts Alvotech's Price Target to $12 From $8, Maintains Hold Rating	23-03-07	MT
Morgan Stanley Starts Alvotech at Equalweight With $10 Price Target	22-09-07	MT
Citigroup Double Downgrades Alvotech to Sell From Buy, Adjusts Price Target to $5 From $12	22-09-06	MT
Citigroup Starts Alvotech at Buy With $12 Price Target	22-07-26	MT
Deutsche Bank Initiates Coverage on Alvotech With Hold Rating, $10 Price Target	22-07-01	MT

More recommendations

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

OUTPERFORM

Number of Analysts

6

Last Close Price

14.15 USD

Average target price

16.5 USD

Spread / Average Target

+16.61%

High Price Target

28 USD

Spread / Highest target

+97.88%

Low Price Target

6 USD

Spread / Lowest Target

-57.60%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Alvotech

Barclays
Citigroup
Deutsche Bank Securities
Morgan Stanley

Ratings for Alvotech

Trading Rating

Investor Rating

ESG Refinitiv

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer